Contract facts
FederalPROTEOMIC AND ANTIBODY PRODUCTION AND CHARACTERIZATION is a federal award for Nih Nci held by Leidos Biomedical Research, Inc. Estimated value $25.7M ($20.5M obligated). Current period of performance ends Sep 12, 2028 (potential Sep 12, 2029). Place of performance: FREDERICK, MD.
PROTEOMIC AND ANTIBODY PRODUCTION AND CHARACTERIZATION
Recompete timing
PublicCurrent PoP ends Sep 12, 2028 (754 days remaining). Agencies typically plan 12–18 months ahead — capture window opens around Mar 12, 2027.
Incumbent footprint
Public recordLeidos Biomedical Research, Inc — $2.1B obligated across 186 awards (firm-wide, all agencies).
Related awards
Same parent · incumbentQuery this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →
Frequently asked questions
What is contract 75N91020F00029?
75N91020F00029 (Proteomic and antibody production and) is a Nih Nci award with an estimated value of $25.7M, currently held by Leidos Biomedical Research, Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.
Which office awarded 75N91020F00029?
Nih Nci awarded 75N91020F00029 to Leidos Biomedical Research, Inc.
Who is the incumbent on 75N91020F00029?
Leidos Biomedical Research, Inc is the incumbent with $2.1B across 186 related awards in SCOUT’s public footprint. The current period of performance ends Sep 12, 2028.
When does Leidos Biomedical Research, Inc’s 75N91020F00029 come up for recompete?
SCOUT tracks a period-of-performance end of Sep 12, 2028. Actual solicitation timing can shift with extensions, bridges, or consolidations.
Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.